AngioDynamics received FDA 510(k) clearance and began international clinical trials in Europe and Hong Kong.
1 report, 0 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AngioDynamics received FDA 510(k) clearance and began international clinical trials in Europe and Hong Kong.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AngioDynamics (United States)
company in California City, United States
Nothing else this week.
- FDA
Related events
- Breakthrough is expanding its clinical trials across Europe and receiving FDA approval for its devices.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA operates under US law to evaluate international clinical data.
- Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
Coverage
Newest first; wire copies grouped- Unknown outlet